Complex Biomarker Discovery Engine

Register interest

More than 850 molecularly targeted cancer drugs are currently in development, or are clinically available, with an average price tag of $100,000 pa. Finding the right target patient population is the key to the commercial success of each, and retargeting or repurposing existing drugs to new populations unlocks substantial untapped revenues for Pharma. The current drug-targeting (biomarker) industry is like internet search beforeGoogle - we look for a single keyword (i.e.mutation) without understanding its nuance, context and importance. This ‘single-gene biomarker’ approach only works in a small proportion of cancers; up to 90% of cancer patients become resistant to targeted drugs. It is more important than ever to develop biomarkers of response to treatment. 

Register interest in OncAI